State Street SPDR S&P Biotech ETF
702 hedge funds and large institutions have $7.06B invested in State Street SPDR S&P Biotech ETF in 2022 Q1 according to their latest regulatory filings, with 124 funds opening new positions, 244 increasing their positions, 183 reducing their positions, and 112 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 244 | Existing positions reduced: 183
11% more first-time investments, than exits
New positions opened: 124 | Existing positions closed: 112
4% more call options, than puts
Call options by funds: $2.7B | Put options by funds: $2.59B
0% more funds holding
Funds holding: 700 → 702 (+2)
0% more funds holding in top 10
Funds holding in top 10: 20 → 20 (0)
7% less capital invested
Capital invested by funds: $7.56B → $7.06B (-$497M)
7.58% less ownership
Funds ownership: 105.38% → 97.79% (-7.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$638M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$301M |
| 3 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$194M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$185M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$161M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$419M |
| 2 |
Jane Street
New York
|
-$225M |
| 3 |
Goldman Sachs
New York
|
-$220M |
| 4 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
-$158M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
-$139M |
XBI Hedge Fund Activity: Q1 2022 in Review
702 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q1 2022, worth a combined $7.06B — down 6.6% from $7.56B a quarter earlier.
Buyers outnumbered sellers: 124 funds opened new XBI positions and 112 closed out — a net gain of 12 holders — while 244 added to existing stakes and 183 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $638M. The largest seller was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, cutting an estimated $419M.
- 702 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q1 2022, up from 700 in Q4 2021.
- Funds reported $7.06B of State Street SPDR S&P Biotech ETF stock for Q1 2022, down 6.6% quarter-over-quarter.
- 124 funds opened new State Street SPDR S&P Biotech ETF positions in Q1 2022 and 112 closed out, a net change of +12 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q1 2022 was Morgan Stanley, an estimated $638M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q1 2022 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $419M sold.
Based on aggregated 13F filings for Q1 2022.